Name | BRD3308 |
---|---|
Synonyms |
BRD3308
Benzamide, 4-(acetylamino)-N-(2-amino-4-fluorophenyl)- 4-Acetamido-N-(2-amino-4-fluorophenyl)benzamide MFCD30187588 |
Description | BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM, displays >20-fold selectivity over HDAC1 and HDAC2, >500-fold selectivity over other HDAC isoforms; attenuates PE-mediated phosphorylation of ERK, but not JNK; also activates HIV-1 transcription in the 2D10 cell line, induces outgrowth of HIV-1 from resting CD4+ T cells isolated from antiretroviral-treated, aviremic HIV+ patients ex vivo and disrupts HIV-1 latency; suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. |
---|---|
References | References 1. Ferguson BS, et al. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9806-11. 2. Barton KM, et al. PLoS One. 2014 Aug 19;9(8):e102684. 3. Wagner FF, et al. ACS Chem Biol. 2016 Feb 19;11(2):363-74. View Related Products by Target HDAC |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 449.9±45.0 °C at 760 mmHg |
Molecular Formula | C15H14FN3O2 |
Molecular Weight | 287.289 |
Flash Point | 225.9±28.7 °C |
Exact Mass | 287.106995 |
LogP | 1.81 |
Vapour Pressure | 0.0±1.1 mmHg at 25°C |
Index of Refraction | 1.689 |